Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
- DOI
- 10.3389/fneur.2024.1332890
- Published
- 2024-01-31
- Container
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fneur.2024.1332890,
title = {Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder},
author = {Stephan Ortiz and Sean J. Pittock and Achim Berthele and Michael Levy and Ichiro Nakashima and Celia Oreja-Guevara and Kerstin Allen and Yasmin Mashhoon and Becky Parks and Ho Jin Kim},
year = {2024},
journal = {Frontiers in Neurology},
doi = {10.3389/fneur.2024.1332890},
url = {https://doi.org/10.3389/fneur.2024.1332890}
}RIS
TY - JOUR TI - Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder AU - Stephan Ortiz AU - Sean J. Pittock AU - Achim Berthele AU - Michael Levy AU - Ichiro Nakashima AU - Celia Oreja-Guevara AU - Kerstin Allen AU - Yasmin Mashhoon AU - Becky Parks AU - Ho Jin Kim PY - 2024 JO - Frontiers in Neurology DO - 10.3389/fneur.2024.1332890 UR - https://doi.org/10.3389/fneur.2024.1332890 ER -
APA
Ortiz, S., Pittock, S. J., Berthele, A., Levy, M., Nakashima, I., Oreja-Guevara, C., Allen, K., Mashhoon, Y., Parks, B., & Kim, H. J. (2024). Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Frontiers in Neurology. https://doi.org/10.3389/fneur.2024.1332890
Source records
- crossref · retrieved 2026-09-27T12:08:22.526Z